Latest news with #VVD-159642
Yahoo
05-04-2025
- Business
- Yahoo
Bayer's Vividion Initiates Dosing in Early-Stage Cancer Study
Bayer's BAYRY wholly owned and independently operated subsidiary, Vividion Therapeutics, Inc, announced that the first patient has been dosed in a phase I study evaluating VVD-159642. VVD-159642 is an investigational oral inhibitor designed to target RAS-driven cancers. The phase I study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of VVD-159642 as a single agent and in combination with either Lumakras (sotorasib) or trametinib in patients with advanced solid tumors. Shares of BAYRY have surged 20.3% year to date compared with the industry's growth of 1.2%. Image Source: Zacks Investment Research VVD-159642 is Vividion's fourth clinical-stage program stemming from its chemoproteomics discovery platform. It is designed to improve patient outcomes by inhibiting RAS-PI3Kα, a key signaling pathway implicated in solid tumor development and progression. Data from preclinical studies on VVD-159642 suggest that the candidate can be evaluated in a broad patient population and might demonstrate increased efficacy in combination with other RAS/MAPK pathway inhibitors. Bayer acquired clinical stage biopharmaceutical company Vividion Therapeutics in 2021 to expand in the field of precision small-molecule therapeutics primarily in oncology and immunology. The chemoproteomics platform technology of Vividion has enabled Bayer to discover a large number of traditionally unaddressable oncological targets with the aid of precision cancer therapeutics. Vividion is currently evaluating an oral KEAP1 activator in solid tumors and an oral STAT3 inhibitor in solid and hematologic malignancies in phase I studies. In December 2024, Vividion acquired Tavros Therapeutics, Inc., a company based in the United States. Tavros' proprietary methods for genomic screening can identify new target opportunities and support discovery and translational efforts toward known targets. 2024 was a challenging year for the company, largely due to strong headwinds in the Crop Science business. The uncertainty caused by ongoing Roundup litigation is also a major hangover on the stock. The guidance for 2025 is pretty ordinary, as Bayer expects business to be challenging. Bayer Aktiengesellschaft price-consensus-eps-surprise-chart | Bayer Aktiengesellschaft Quote In this scenario, the company aims to strengthen its pharmaceutical pipeline. Bayer has expanded its pipeline in new modalities of cell therapy, through the acquisition of BlueRock, and gene therapy, through the acquisition of AskBio. Bayer had earlier collaborated with Thermo Fisher Scientific Inc. to jointly develop diagnostic tests based on next-generation sequencing. The company recently announced a licensing agreement with Suzhou Puhe BioPharma Co., a clinical-stage biotechnology company. Suzhou Puhe BioPharma is focused on the research and development of innovative small-molecule precision therapeutics. The companies have collaborated for Suzhou Puhe BioPharma's oral, small molecule protein arginine N-methyltransferase 5 (PRMT5) inhibitor that selectively targets methylthioadenosine phosphorylase (MTAP)-deleted tumors. Under the agreement, Bayer obtained an exclusive worldwide license to develop, manufacture and commercialize the MTA-cooperative PRMT5 inhibitor. Sales growth was encouraging in the Pharmaceutical division in 2024. New products, Nubeqa and Kerendia, retained their impressive momentum and offset the negative impact of a decline in Xarelto sales. The company is working to expand the labels of its key drugs, Nubeqa and Kerendia, which should boost growth. BAYRY currently carries a Zacks Rank #2 (Buy). A couple of other top-ranked stocks in the pharma/biotech sector are Gilead Sciences, Inc GILD and Dynavax Technologies Corporation DVAX, each carrying a Zacks Rank #2 at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. In the past 60 days, Gilead Sciences' EPS estimate for 2025 has increased from $7.55 to $7.87. During the same timeframe, the figure for 2026 has increased to $8.31 from $8.17. Shares of GILD have surged 22.5% year to date. GILD's earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.47%. In the past 30 days, estimates for Dynavax's 2025 EPS have remained constant at 33 cents. During the same time frame, EPS estimates have remained constant at 57 cents for 2026. In the past six months, shares of DVAX have gained 19.3%. DVAX's earnings beat estimates in three of the trailing four quarters and missed the same in the other one, the average surprise being 9.58%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Dynavax Technologies Corporation (DVAX) : Free Stock Analysis Report Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
03-04-2025
- Business
- Yahoo
Vividion Therapeutics Doses First Patient in Phase I Study of RAS-PI3Kα Inhibitor for Treatment of Advanced Solid Tumors
VVD-159642, Vividion's fourth clinical-stage program stemming from its chemoproteomics discovery platform, is designed to improve patient outcomes by inhibiting RAS-PI3Kα, a key signaling pathway implicated in solid tumor development and progression Preclinical data support clinical trials with a broad patient population, and may deliver increased efficacy in combination with other RAS/MAPK pathway inhibitors Approximately 20 percent of all cancers are driven by mutations of the RAS family of genes1 Vividion continues to advance the chemoproteomics technology platform with goal to unlock disease-causing, yet traditionally undruggable targets with precision small-molecule therapeutics SAN DIEGO & BERLIN, April 03, 2025--(BUSINESS WIRE)--Vividion Therapeutics, Inc. (Vividion) today announced that the first patient has been dosed in a Phase I clinical trial evaluating VVD-159642, an investigational oral inhibitor designed to target RAS-driven cancers. Vividion is a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, utilizing innovative discovery technologies to unlock targets with strong disease-link, yet traditionally undruggable and develop small molecule precision therapeutics for devastating cancers and immune disorders. The new Phase I study (NCT06804824) will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of VVD-159642 as a single agent and in combination with either sotorasib or trametinib in patients with advanced solid tumors. "Despite being a major driver in approximately 20% of cancers, the RAS gene has proven exceptionally difficult to target with drugs, largely due to its essential role in the RAS-PI3Kα signaling pathway, which is vital for healthy cell function," said Jenna Goldberg, M.D., Chief Medical Officer of Vividion. "VVD-159642 is designed and being studied to selectively prevent RAS activation of the PI3Kα pathway, thus blocking oncogenic signaling without disrupting normal cellular function. Preclinical studies of VVD-159642 give us confidence in its potential to inhibit tumor growth while avoiding the on-target toxicities that have limited prior attempts to drug this important target. In addition to providing a more tolerable alternative to current therapies, we believe that VVD-159642 has potential to treat a broad patient population, including in both RAS-mutant and HER2-overexpressed tumors, and may deliver increased efficacy in combination with other RAS/MAPK pathway inhibitors." "We're excited to bring our fourth innovative oncology asset into the clinic, which not only represents continued validation of Vividion's covalent-first chemoproteomics platform but also provides a potential new treatment option for patients with RAS-driven cancers," said Aleksandra Rizo M.D., Ph.D., Chief Executive Officer of Vividion. "The team at Vividion is rapidly advancing scientific innovations into clinical development that have the potential to address multiple devastating diseases not reachable by current therapies," said Christian Rommel, Ph.D., Head of Research and Development at Bayer's Pharmaceuticals Division. "The initiation of this clinical trial marks a significant step forward in leveraging Vividion's innovative drug discovery approach to target a highly relevant signaling pathway and bring a potential new treatment option to people suffering from difficult-to-treat cancers." Vividion also has ongoing Phase I trials evaluating an oral KEAP1 activator in solid tumors and oral STAT3 inhibitor in solid and hematologic malignancies. The company is advancing multiple innovative drug discovery programs toward the clinic and has a rich pipeline of opportunities emerging in early discovery in the fields of oncology and immunology. About VividionVividion Therapeutics, Inc., a wholly owned and independently operated subsidiary of Bayer AG, is a clinical stage biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders. The company's platform has enabled it to identify hundreds of previously unknown functional pockets on well-validated protein targets implicated in a wide range of diseases, while simultaneously identifying compounds from its proprietary covalent chemistry library that interact in a highly selective manner with those pockets. The company is leveraging its proprietary chemoproteomic platform to advance a diversified pipeline of highly selective small molecule therapeutics targeting high value, traditionally undruggable targets in oncology and immunology. For more information, please visit About BayerBayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, "Health for all, Hunger for none," the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to Find more information at Follow us on Facebook: aka (2025-0057) Forward-Looking StatementsThis release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Reference: 1. Ian A. Prior et al "The Frequency of RAS Mutations in Cancer". Cancer Res (2020) 80 (14): 2969–2974. Available at: Accessed: March 2025. View source version on Contacts Bayer Global Media Contact:Derin Denham, phone +1 973 610 7324 Email: Contact for media inquiries Bayer U.S.: Elaine Colon, phone +1 732 236 1587 Email: Vividion Media Contact: Laurie Sherman, phone +1 858 630 8246 Email: media@
